#South Korea #Seoul #Hanmi Pharmaceutical #BH3120 #Cancer Immunotherapy

Progress of BH3120 in Cancer Immunotherapy

Recently, Hanmi Pharmaceutical, alongside Beijing Hanmi Pharmaceutical, presented remarkable advancements regarding their collaborative therapy, BH3120 at the Society for Immunotherapy of Cancer (SITC) conference in Houston, USA. This novel cancer treatment based on Hanmi’s unique dual-antibody platform, named Pentambody, opens new avenues for targeted cancer therapies.

What is BH3120?

BH3120 is a groundbreaking immunotherapy designed to enhance the body's immune response against cancer cells. This powerful drug is engineered to simultaneously bind to two distinct targets; PD-L1 found on tumor cells and 4-1BB present on immune cells. This dual action creates a bridge facilitating the recognition and extermination of tumor cells by immune cells, thereby improving the overall efficacy of cancer treatments.

Clinical Findings

In the ongoing Phase-1 study, which evaluates BH3120 as a standalone treatment for advanced solid tumors, the trial has shown promising results without encountering any dose-limiting toxicities or severe adverse events so far. Dr. Dong-wan Kim, the lead investigator from Seoul National University Hospital, praised the preliminary outcomes, stating that the study represents a vital step in validating the potential of this next-generation immunotherapy.

The Phase-1 clinical trial is critical for determining the safety and tolerability of BH3120. To date, the clinical trial has progressed smoothly through the third cohort, and no significant safety issues have arisen, giving researchers optimism about the findings and future developments.

Combined Approach

In addition to testing BH3120 as a monotherapy, Hanmi is evaluating it in conjunction with MSD’s anti-PD-1 therapy, KEYTRUDA (Pembrolizumab). This recent combination study, approved by both Korean and US regulatory authorities, aims to bolster the effectiveness of BH3120 while potentially minimizing the side effects often associated with conventional immunotherapies.

With the clinical development of this combination anticipated to ramp up early next year, Hanmi stands at the forefront of innovation in immuno-oncology. Young Su Noh, head of Hanmi's ONCO clinical team, emphasized that the BH3120 study marks a significant milestone as it is the first global clinical research project employing their proprietary Pentambody platform. He expressed hope that these efforts will yield a groundbreaking cancer treatment that overcomes the limitations of current therapies.

Future Prospects

As researchers continue to unravel the potential of BH3120 in treating patients with advanced solid tumors, the excitement within the field of cancer immunotherapy grows. The findings shared at the SITC conference underscore a meaningful advancement in the quest for effective cancer treatments that could reshape the future landscape of cancer care. As studies progress, there is hope that this innovative therapy could not only combat cancer more effectively but also offer patients a safer alternative with fewer side effects.

The discussions around BH3120 signify a beacon of hope for patients battling cancer, echoing how advancements in science and biotechnology can lead to the development of novel and transformative therapies. Keeping an eye on Hanmi Pharmaceutical and its clinical trials could provide significant insights into the promising future of cancer treatment.

For more information, visit Hanmi Pharmaceutical.